<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00239382</url>
  </required_header>
  <id_info>
    <org_study_id>107.266</org_study_id>
    <nct_id>NCT00239382</nct_id>
  </id_info>
  <brief_title>A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Open-labelled Study to Compare the Efficacy and Safety of Meloxicam 15 mg IM Ampoules Once Daily and Meloxicam 15 mg Tablets Administered Orally Once Daily Over a Period of 7 Days in Patients With RA.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this trial was to assess the efficacy and safety of 15 mg meloxicam i.m.&#xD;
      once daily compared with 15 mg meloxicam tablets once daily p.o. in patients with Rheumatoid&#xD;
      arthritis over a time period of 7 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized (1:1), open-label, multi-center, active-control, parallel-group study&#xD;
      to compare the efficacy of 15 mg meloxicam i.m. once daily compared with 15 mg meloxicam&#xD;
      tablets once daily p.o. in patients with rheumatoid arthritis over a time period of 7 days.&#xD;
&#xD;
      Patients eligible for the trial who met all inclusion and exclusion criteria and who gave&#xD;
      their informed consent were randomized to one of two treatment groups (i.e. meloxicam ampoule&#xD;
      or meloxicam tablet).&#xD;
&#xD;
      The study period totaled 8-14 days included screening, randomisation, study drug&#xD;
      administration, and 7-day follow-up. The relevant assessment were performed on the day of&#xD;
      randomisation and 7-day follow up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2004</start_date>
  <completion_date type="Actual">December 31, 2004</completion_date>
  <primary_completion_date type="Actual">December 1, 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient's assessment of overall pain</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient's global assessment of disease activity</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment of Disease Activity</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tender/Painful Joint Count</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swollen Joint Count</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Morning Stiffness</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's assessment of physical function</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Global Assessment of Efficacy by Patient</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Global Assessment of Efficacy by Investigator</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawals due to Inadequate Efficacy</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Status With Regard to Arthritic Condition as Assessed by the Patient</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Status With Regard to Arthritic Condition as Assessed by the Investigator</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of Analgesic Action</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Pain Relief After the First Trial Drug Administration</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paracetamol Consumption</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <enrollment>150</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam ampoule</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam tablet</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 18 years or above&#xD;
&#xD;
          -  The patient has rheumatoid arthritis, as defined by the American Rheumatism&#xD;
             Association.&#xD;
&#xD;
          -  Assessment of overall pain (by the patient), after a washout for NSAID of at least 2&#xD;
             days (3 days for oxicams), must exceed 40 mm on a 100 mm visual analogue scale (VAS)&#xD;
&#xD;
          -  Symptoms of RA requiring administration of NSAIDs&#xD;
&#xD;
          -  Outpatients&#xD;
&#xD;
          -  Willingness and ability to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hypersensitivity to the trial drugs or their excipients,&#xD;
             analgesics, antipyretics or NSAIDs&#xD;
&#xD;
          -  Any clinical evidence of active peptic ulceration during the previous 6 months&#xD;
&#xD;
          -  Pregnancy or breastfeeding (precaution: attention should be drawn to reports that&#xD;
             NSAIDs were reported to decrease the effectivity of intrauterine devices)&#xD;
&#xD;
          -  Asthma, nasal polyps, angioneurotic oedema or urticaria following the administration&#xD;
             of aspirin or NSAIDs&#xD;
&#xD;
          -  Concomitant treatment with anti-coagulants (including heparin), lithium&#xD;
&#xD;
          -  Concomitant administration of other NSAIDs or analgesic agents (except paracetamol up&#xD;
             to 4g/day)&#xD;
&#xD;
          -  Administration of any NSAID during the last 2 days (3 days for any oxicam) prior to&#xD;
             the first administration of the trial drug&#xD;
&#xD;
          -  Concomitant treatment with methotrexate, sulfasalazine, D-penicillamine, chloroquine&#xD;
             or any other disease modifying antirheumatic drug initiated or with an altered dose&#xD;
             over the previous 3 months&#xD;
&#xD;
          -  Concomitant treatment with an oral corticosteroid initiated or with an altered dose&#xD;
             over the previous month&#xD;
&#xD;
          -  Parenteral or intraarticular administration of corticosteroids in the previous month&#xD;
&#xD;
          -  Any i.m. injection during the previous 7 days&#xD;
&#xD;
          -  Synovectomy and/or surgical treatment for RA in the previous month or during the trial&#xD;
&#xD;
          -  Any physiotherapy which will be changed during the trial&#xD;
&#xD;
          -  Any contra-indication to i.m. injections&#xD;
&#xD;
          -  Clinical evidence of or known severe cardiac, hepatic, renal, metabolic,&#xD;
             haematological disease, mental disturbance, ulcerative colitis&#xD;
&#xD;
          -  Any other rheumatological or non-rheumatological disease that could interfere with the&#xD;
             evaluation of efficacy and safety&#xD;
&#xD;
          -  Serum creatinine 125 % of the upper limit of normal range ; aspartate&#xD;
             amino-transferase (AST/SGOT) and/or alaline amino-transferase (ALT/SGPT) 200 % of the&#xD;
             upper limit of normal range&#xD;
&#xD;
          -  Platelet count &lt; 100,000/mm3 ; leucocytes count &lt; 3,000/mm3&#xD;
&#xD;
          -  Participation in another clinical trial during this study or during the previous month&#xD;
&#xD;
          -  Previous participation in this trial (i.e. having been allocated a randomized&#xD;
             treatment number)&#xD;
&#xD;
          -  Patient unable to comply with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim Shanghai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>People's Hospital, Beijing University</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Xuan Wu Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Affiliated, Anhui Medical University</name>
      <address>
        <city>Hefei City, Anhui Province</city>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital, Shang Dong University</name>
      <address>
        <city>Nan City</city>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Guanghai Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200443</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/107/107.266_U06-3613.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>October 13, 2005</study_first_submitted>
  <study_first_submitted_qc>October 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2005</study_first_posted>
  <last_update_submitted>August 1, 2018</last_update_submitted>
  <last_update_submitted_qc>August 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

